Park S M, Park S J, Kim H J, et al. A known expressed sequence tag, BM742401, is a potent lincRNA inhibiting cancer metastasis[J]. Experimental and Molecular Medicine, 2013, 45: e31.
[2]
Sousa J F, Torrieri R, Silva R R, et al. Novel primate-specific genes, RMEL 1, 2 and 3, with highly restricted expression in melanoma, assessed by new data mining tool[J]. PLoS One, 2010, 5(10): e13510.
[3]
Orentas R J, Nordlund J, He J, et al. Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison[J]. Frontiers in Oncology, 2014, 4: 134.
[4]
Chu C M, Yao C T, Chang Y T, et al. Gene expression profiling of colorectal tumors and normal mucosa by microarrays meta- analysis using prediction analysis of microarray, artificial neural network, classification, and regression trees[J]. Disease Markers, 2014, 2014: 634123.
[5]
Leslie R, O'Donnell C J, Johnson A D. GRASP: Analysis of genotypephenotype results from 1390 genome- wide association studies and corresponding open access database[J]. Bioinformatics, 2014, 30(12): i185-i194.
[6]
Laversin S A, Phatak V M, Powe D G, et al. Identification of novel breast cancer-associated transcripts by UniGene database mining and gene expression analysis in normal and malignant cells[J]. Genes Chromosomes Cancer, 2013, 52(3): 316-329.
[7]
Aouacheria A, Navratil V, Barthelaix A, et al. Bioinformatic screening of human ESTs for differentially expressedgenes in nomal and tumor tissues[J]. BMC Genomics, 2006, 7: 94.
[8]
Barlow D J, Edwards M S, Thornton J M. Continuous and discontinuous protein antigenic determinants[J]. Nature, 1986, 322(6081): 747-748.
[9]
Liu W Q, Vidal M, Olszowy C, et al. Structure-activity relationships of small phosphopeptides, inhibitors of Grb2 SH2 domain, and their prodrugs[J]. Journal of Medicinal Chemistry, 2004, 47(5): 1223-1233.
[10]
Mandal P K, Ren Z, Chen X, et al. Structure- activity studies of phosphopeptidomimetic prodrugs targeting the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3 (Stat3) [J]. International Journal of Peptide Research and Therapeutics, 2013, 19 (1): 3-12.
[11]
Chen K F, Tai W T, Chu P Y, et al. STAT3 mediates regorafenibinduced apoptosis in hepatocellular carcinoma[J]. Clinical Cancer Research, 2014, 20(22): 5768-5776.
[12]
Sanz A, Niranjan Y, Hammarén H, et al. The JH2 domain and SH2- JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains[J]. Biochimica et Biophysica Acta, 2014, 1844(10): 1835-1841.
